# CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

> **NCT04656418** · PHASE3 · COMPLETED · sponsor: **CSL Behring** · enrollment: 64 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **BIOLOGICAL:** CSL312
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04656418
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-27
- **Primary completion:** 2022-06-07
- **Final completion:** 2022-06-07
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04656418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04656418, "CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04656418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*